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Jason C. Kovacic, MD, PHDS ometimes, ﬁelds of scientiﬁc inquiry suddenlyappear on the basis of a new piece of equip-ment, technique, or approach. The direction
of such research is often dictated by the new tool’s
nature rather than important scientiﬁc questions.
This research will endure if it leads to subsequent dis-
covery; if not, it will be discarded. Conversely,
exciting new avenues of research may spring from
seminal scientiﬁc discoveries destined to reshape
the way we approach biology and disease, with the
available tools and technologies barely adequate to
probe fundamental new questions that arise. The dis-
covery of micro–ribonucleic acid (miRNA) in the early
1990s falls squarely into the latter category (1).
The miRNAs belong to the family of noncoding
RNAs and are highly conserved, small (w22 nucleo-
tides), single-stranded RNAs that modulate gene ex-
pression. Their usual mode of action is to bind to the
3’ untranslated regions of speciﬁc target messenger
RNAs (mRNAs [the RNA moiety fated to be translated
into protein]) to suppress mRNA activity and trans-
lation, thereby governing protein expression.
As with mRNA and other RNA moieties, miRNAs
may play a local intracellular role in regulating gene
expression within the same cell that produces them.
However, miRNAs also exist in extracellular locations
such as blood, urine, and other bodily ﬂuids (2,3).
Furthermore, although mRNAs are highly unstable*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From The Zena and Michael A. Wiener Cardiovascular Institute, Icahn
School of Medicine at Mount Sinai, New York, New York, and the Marie-
Josée and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai
School of Medicine, New York, New York. Dr. Kovacic has received
research support from the National Institutes of Health (K08HL111330),
AstraZeneca, the American Heart Association (14SFRN20490315;
14SFRN20840000), and The Leducq Foundation (Transatlantic Networks
of Excellence Award).when outside the intracellular milieu, miRNAs may
exist in a stable extracellular form, protected from
degradation. Indeed, nature seems to have gone to
great lengths to protect certain extracellular miRNAs
from degradation, with multiple protective mecha-
nisms identiﬁed, including association with other
complexes, such as high-density lipoprotein (HDL)
particles (4), Argonaute-2 (5), or packaging in lipid
vesicles or particles (6).
With this identiﬁcation as a stable entity in these
extracellular compartments, researchers were quick
to investigate associations between circulating miR-
NAs and various forms of cardiovascular disease
(CVD). In just a few years, accumulating evidence has
demonstrated strong associations between levels of
speciﬁc circulating miRNAs and acute myocardial
infarction, coronary artery disease, heart failure,
stroke, hypertension, and other CVDs (as reviewed by
Creemers et al. [7]). Although miRNAs are exciting in
this context and offer great promise as biomarkers of
disease, an important series of questions has arisen
from this research that relates speciﬁcally to extra-
cellular miRNAs in the circulation:
 From where in the body do these circulating
miRNAs originate?
 Do circulating miRNAs serve a predetermined bio-
logic purpose?
 Do circulating miRNAs have biologic targets, and
what are they?
These questions are especially poignant, as the
seemingly elaborate and unique mechanisms that
exist to protect circulating extracellular miRNAs from
degradation can be taken as strong (albeit indirect)
evidence to suggest that they play amajor biologic role.SEE PAGE 2526In this issue of the Journal, Shan et al. (8) provide
answers to these questions. Their study began with an
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2539astute, earlier observation that miR-223 can be readily
detected in vascular cells from the uninjured rat ca-
rotid artery, with a further 3-fold increase in miR-223
levels detected 7 days after vascular injury (9).
Although miR-223 was only 1 of w100 miRNAs that
were found to be of potential importance, miR-223
stood out because it was previously thought to be
restricted in expression to hematopoietic cells. We
now know that hepatocytes also produce miR-223 (10);
its production, however, had not been demonstrated
in vascular cells. To their credit, Shan et al. chose to
pursue this apparent anomaly and were ultimately
able to describe the origin, target, and functional role
of miR-223 in the vasculature. Although miR-223 has
been detected in other tissues, and its effects extend
beyond the vasculature (10–12), major new ﬁndings of
the present study include that: 1) miR-223 is the most
abundant miRNA in platelets, monocytes, blood mi-
croparticles, and serum, which is consistent across
humans, mice, and rats; 2) miR-223 is essentially ab-
sent fromvascular smoothmuscle cells (VSMCs) grown
in isolation in vitro, butmacrophages producemiR-223
that can be taken up and subsequently identiﬁed in
VSMCs; 3) miR-223 is more abundant in the serum and
diseased arterial wall of both mice and humans with
atherosclerosis versus controls without atheroscle-
rosis; 4) miR-223 promotes VSMC apoptosis while
inhibiting proliferation and migration; 5) miR-223
binds to insulin-like growth factor 1 receptors, lead-
ing to inhibition of the PI3K-Akt pathway (known to
be associated with the cell cycle, quiescence, and
proliferation); and 6) miR-223 inhibition in vivo leads
to increased atherogenesis and increased neointimal
formation after arterial injury (8).
Although this research clearly represents an elegant
and extensive characterization of miR-223 in the
vascular system, not all of these data are novel
(4,13,14). Furthermore, miR-223 was recently shown
to regulate cholesterol homeostasis, with miR-223
knockout mice exhibiting increased hepatic, total,
and HDL cholesterol levels (10). As a potential limita-
tion of the study by Shan et al. (8), it is unclear if the
cholesterol-related effects of miR-223 may have
affected their in vivo atherogenesis ﬁndings. Never-
theless, and despite this concern, this new study’s true
strength is that it “puts it all together,” demonstrating
a precise pathobiologic miR-223 pathway in VSMCs,
making it one of only a few studies to depict the
complete extent of how and where a speciﬁc circu-
latingmiRNA is produced, how itmoves from source to
target cell, its role in modulating a key intracellular
signaling pathway, and ﬁnally its biologic effect.
Among the few comparable in vivo vascular studies
(Figure 1), Zhang et al. (15) showed that miR-150 isproduced by monocytes, packaged into microvesicles,
and secreted to be taken up by endothelial cells, where
it reduces c-Mybproteinexpression toultimately affect
endothelial cell migration. Especially relevant to the
currentpaper (8) in the Journal, Tabet et al. (16) recently
demonstrated that miR-223 is carried in the blood
by HDL and transferred to endothelial cells, where it
directly represses intercellular adhesion molecule 1
expression and function. Additional studies have
shown that endothelial cell–derivedmiRNAsalsoplay a
role in atherogenesis and vascular remodeling (17–19).
In addition to the vasculature, investigators have
begun to dissect pathways of miRNA production,
trafﬁcking, and signaling in other biologic systems.
Chen et al. (20), for example, have suggested that
cardiac progenitor cells produce and secrete miR-451,
which can reduce oxidative stress and apoptosis in
cardiomyocytes. Nevertheless, publications such as
these are few, and our in-depth understanding of the
entire “life-cycle” of speciﬁc miRNAs in the cardio-
vascular system remains sparse. Therefore, the cur-
rent paper represents a small but critical piece of this
overall puzzle, demonstrating an important function
for miR-223 in the vascular system.
Apart from being an elegant characterization of the
vascular life-cycle of miR-223, the work by Shan et al.
(8) also highlights the substantial clinical opportu-
nities that have arisen in terms of potentially modu-
lating atherosclerosis and other CVDs by directly
targeting endogenous miRNAs or other noncoding
RNA moieties (21). Indeed, their ﬁnding that inhibi-
tion of miR-223 increases atherogenesis argues for the
possibility that augmenting miR-223, or increasing its
effect or signaling pathway(s), might be a viable
therapeutic strategy. However, the speciﬁc road to
clinical translation for miR-223 may not be straight-
forward. The fact that miR-223 also decreases VSMC
proliferation and migration while increasing apo-
ptosis suggests that caution is required because VSMC
apoptosis and impaired function may be associated
with weakening of the atherosclerotic ﬁbrous cap and
plaque instability in advanced lesions (22). Therefore,
although miR-223 might reduce atherosclerotic pla-
que area, it could be a “double-edged sword” and
increase the tendency for plaque rupture.
These issues notwithstanding, while we continue to
search for endogenous noncoding RNAs that hold
promise as therapeutic targets, it is noteworthy that
the clinical landscape is likely about to witness an ex-
plosion of novel therapies using the complimentary
approach of exogenously administering inhibitory
RNAs to modulate gene expression. This new thera-
peutic wave was set in motion by the discovery of the
process of RNA interference (RNAi), which ultimately
FIGURE 1 Pathways of Vascular miRNAs
Recent in vivostudies elucidated theorigin, target, signaling, and actions ofmicro ribonucleic acids (miRNAs;miR) in thevasculature (8,15–19). BCL2¼B-cell lymphoma2; EC¼
endothelial cell; FOXO3¼ forkhead box O3; HDL¼ high-density lipoprotein; ICAM ¼ intercellular adhesion molecule; IGF-1R¼ insulin-like growth factor 1 receptor; IRS1 ¼
insulin receptor substrate 1; KLF2¼Krüppel-like factor 2;MP¼microparticle; prolif¼proliferation;PI3K¼phosphatidylinositol 3-kinase; VSMC¼ vascular smoothmusclecell.
Kovacic J A C C V O L . 6 5 , N O . 2 3 , 2 0 1 5
Unlocking miRNA J U N E 1 6 , 2 0 1 5 : 2 5 3 8 – 4 1
2540led to the awarding of the 2006 Nobel Prize in Physi-
ology or Medicine. Numerous studies are now under-
way seeking to modulate important biologic processes
by using RNAi-based therapies, and it seems only a
matter of time before the ﬁrst of these therapies enters
our pharmacological armamentarium. Furthermore, in
addition to miRNA, several other noncoding RNA
moieties are under intense investigation (e.g., long
noncoding RNA), and although far less is presently
known about these other RNAs, it seems they almost
certainly have a major role in the cardiovascular sys-
tem and may hold promise as therapeutic targets (23).
Whether it is by harnessing the power of RNAi, or
by identifying and targeting endogenous noncoding
RNAs that are key biologic players, we have goodreason to be excited about the remarkable discoveries
that have led us to this point and the subsequent
advances in our understanding of biology and medi-
cine. Ultimately, this great progress in unlocking the
many secrets of noncoding RNA augurs well for the
future care of our patients.
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